Dharti Proteins Limited has filed its Thirty-First Annual Report for the financial year 2024-25 with the Bombay Stock Exchange. The communication, dated May 13, 2026, clarifies that the company had undergone the Corporate Insolvency Resolution Process (CIRP) and was subsequently revived following an order by the National Company Law Tribunal, Ahmedabad Bench, on November 18, 2025. The new management took over the company's affairs on December 19, 2025, and has since focused on stabilizing operations and regularizing compliance.

Financial Performance

The company reported a net loss of ₹0.66 lakh for the year ended March 31, 2025, compared to a net loss of ₹19.01 lakh in the previous year. Income from operations remained nil for both years, while other income stood at ₹7.20 lakh for 2024-25 against nil in the prior year. Total expenditure for the year was ₹7.87 lakh, down from ₹19.01 lakh in 2023-24. The basic and diluted earnings per share (EPS) for the year was reported at (0.01), an improvement from (0.18) in the previous year.

Auditor's Observations

The Independent Auditor’s Report issued by N.S. Nanavati & Co. carries a qualified opinion. The auditors noted that the company has been inoperative for several years with no trading or manufacturing activities. They highlighted substantial doubt regarding the company's ability to continue as a going concern due to negative financial indicators and the absence of formal financial support. Additionally, the report cited non-compliance with the maintenance of accounting software audit trails and outstanding statutory dues, including income tax and sales tax amounts pending for more than six months.

Compliance and Governance

The company stated that the delay in filing the annual report was due to the circumstances prevailing during the CIRP period and the subsequent transition. The present management has taken steps to complete the requisite compliance as a measure of good corporate governance. The company remains committed to adhering to all statutory and regulatory requirements and strengthening its compliance framework going forward.

Dharti Proteins Limited has officially communicated to the Bombay Stock Exchange that it does not fall under the Large Corporate framework as defined by the Securities and Exchange Board of India. The declaration, submitted on April 13, 2026, clarifies the company's regulatory compliance status regarding debt securities disclosure requirements.

Regulatory Framework Declaration

The company's declaration references specific SEBI circulars SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, and SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023. These circulars establish the framework for fund raising through debt securities issuance by Large Corporates and mandate specific disclosure compliance requirements.

Compliance Implications

The non-applicability of the Large Corporate framework means Dharti Proteins Limited is exempt from filing the Initial Disclosure in Annexure "A" as required under BSE circulars for the year ended March 31, 2026. This exemption is based on the company not meeting the applicability criteria outlined in the SEBI operational circular dated August 10, 2021.

Company Profile

Dharti Proteins Limited operates from its registered office at A-1115, Titanium Business Park, Near Makarba Underpass, Makarba, Ahmedabad. The company's declaration was signed by Twinkle Bipinchandra Gajjar, Company Secretary and Compliance Officer, and Sohan Lal, Chief Financial Officer, confirming the accuracy of the submitted information.

The formal declaration ensures regulatory clarity and maintains the company's compliance status with stock exchange requirements while confirming its position outside the Large Corporate regulatory framework.